Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

NCT01849562 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: Sovaprevir
DRUG: ACH-3102
DRUG: Ribavirin
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.

Collaborators

[object Object]